Initial analysis of PainVision system in quantitative assessment of cancer pain and chemotherapy-induced neuropathy
10.19401/j.cnki.1007-3639.2016.12.010
- VernacularTitle:PainVision系统量化评估癌痛及化疗神经毒性的应用分析
- Author:
Yu ZHAO
;
Sen YANG
;
Yi YU
;
Hui WANG
;
Kun ZHAO
;
Huaxin ZHAO
;
Qing XU
- Keywords:
Cancer pain assessment;
PainVision system;
Chemotherapy-induced neuropathy
- From:
China Oncology
2016;26(12):1025-1030
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Cancer-related pain is one of the most important symptoms of patients with advanced cancer. Chemotherapy sometimes induces peripheral neuropathy and pain. These symptoms seriously affect patients’ quality of life. Cancer pain assessment is now achieved by the subjective scales of patients, but lacking objective measurement. In this study, we used the neurotic electrophysiological method by way of PainVision system (PV system) to evaluate cancer pain quantitatively to detect and analyze degree of chemotherapy-induced neuropathy. Methods:We obtained numerical rating scale (NRS) scores from patients receiving analgesics and calculated the PainRatio from PV system at the same time. Then we analyzed the relationship between NRS and PainRatio scores. We detected current perception threshold (CPT) levels of patients receiving chemotherapy to ifnd the correlation between chemotherapy and CPT level, and attempt to evaluate chemotherapy-induced neuropathy.Results:PainRatio scores were linearly associated with NRS scores (Pearson correlation coeffcient=0.849,P<0.001). Patients with neuropathy symptoms got higher CPTs. However, no statistically signiifcant difference was observed between patients treated with oxaliplatin, paclitaxel and other agents.Conclusion:PainVision system can be used in cancer pain assessment quan-titatively, and be helpful in cancer pain assessment objectively. Patients with deifned neuropathy showed higher CPTs, indicating the potential clinical value of PV system in detecting and evaluating chemotherapy-induced neuropathy.
